Compare Expeditors International of Wshngtn Inc (EXPD) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Sanofi SA — how do they compare? Expeditors International of Wshngtn Inc trades at $193.36 (market cap $25.18B), while Sanofi SA trades at $40.02 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3.8× Expeditors International of Wshngtn Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and Sanofi SA for 94 Days on average.
| EXPD | SNY | |
|---|---|---|
Market Cap | $25.18B | $95.18B |
Volume | 1,003,557 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $194.12 | $52.34 |
52-Week Low | $113.13 | $39.51 |
Typical Hold Time | 43 Days | 94 Days |
Enterprise Value | $24.72B | $114.48B |
Dividend Yield | 0.84% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $190.85, down 0.5% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 expected at $2.20 EPS. Revenue growth is steady, rising from $10.6B in 2024 to a projected $12.0B in 2026, while net income margins remain stable around 7.6%. Recent news highlights efficiency initiatives and airfreight demand as positive catalysts.
Outlook is mixed: strong profitability and earnings beats support upside, but a high P/E of 28.2 suggests premium valuation risks. Analyst consensus is cautious with 63.6% hold ratings, and the consensus price target of $179.43 implies potential downside. Key risks include freight market volatility and execution challenges amid economic uncertainty.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
